Mineralocorticoid receptor antagonists for heart failure (Q37955919)

25 August 2017

title

Mineralocorticoid receptor antagonists for heart failure (English)

1 reference

25 August 2017

0 references

Arthur Mark Richards

1 reference

25 August 2017

language of work or name

English

0 references

publication date

14 November 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

1 reference

25 August 2017

1 reference

25 August 2017

page(s)

2801-2815

1 reference

Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Evidence for secretion of an aldosterone-stimulating hormone by the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

The role of the renin-angiotensin system in the control of aldosterone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Control of aldosterone secretion: a model for convergence in cellular signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone and mineralocorticoid receptors in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

High rate of detection of primary aldosteronism, including surgically treatable forms, after ???non-selective??? screening of hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Distinguishing the antihypertensive and electrolyte effects of eplerenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Mineralocorticoid-induced increase in beta-adrenergic receptors of cultured rat arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Pathophysiological effects of aldosterone in cardiovascular tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Rapid actions of aldosterone in vascular health and disease--friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Rapid nongenomic effects of aldosterone on human forearm vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone induces contraction of the resistance arteries in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Lack of rapid aldosterone effects on forearm resistance vasculature in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

From inflammation to fibrosis: a stiff stretch of highway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone and vascular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone is produced from ventricles in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone production is activated in failing ventricle in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

The clinical implications of aldosterone escape in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Spironolactone improves lung diffusion in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effects of Spironolactone and Metoprolol on QT Dispersion in Heart Failere

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Use of aldosterone antagonists in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

10.1517/14656566.2011.631524

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference